Cerevel Therapeutics, a company focused on neuroscience diseases, announced the completion of its merger with Arya Sciences Acquisition Corp II (Nasdaq: ARYBU). Cerevel Therapeutics will commence trading its shares under the symbol “CERE” and its warrants under the symbol “CEREW” today on the Nasdaq. Net proceeds totaled approximately $440 million, which included funds held in Arya II’s trust account and the concurrent PIPE financing. Arya II shareholders approved the transaction Oct. 26. Cerevel Chairman and Chief Executive Officer Tony Coles, M.D., will continue to lead the combined company. Read more.
Cerevel Therapeutics Debuts on Nasdaq
